FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2130462370> ?p ?o ?g. }

• W2130462370 endingPage "6" @default.
• W2130462370 startingPage "190" @default.
• W2130462370 abstract "Atopic dermatitis (AD) is a common chronic skin disease, and a significant percentage of AD patients have severe forms. Inflammation based on type 2 helper T cells (T(H)2), autoantibodies, and CD8+ T cells could play a relevant role in this disease. When the patient requires systemic immunosuppressors for disease control, side effects are frequent. We propose a sequential therapeutic strategy with 2 monoclonal antibodies, omalizumab (anti-immunoglobulin [Ig] E) and rituximab (anti-CD20), which might induce clinical benefit with few side effects in selected individuals with AD.We report 6 cases of severe AD refractory to conventional therapy. The patients underwent sequential switch therapy with omalizumab and rituximab. Clinical response was assessed by means of the decrease in body surface affected. Immunological parameters and side effects were also monitored.Four patients received omalizumab before a high-dose cycle of rituximab. In the case of recurrences, either low-dose cycles of rituximab or omalizumab were administered. A long-term clinical benefit was observed in 3 out of 4 patients. Two patients first received high-dose rituximab followed by either low-dose rituximab or omalizumab, and one of them achieved a response at 17 months. No severe side effects were recorded. Serum IgE level and B-cell counts decreased with therapy, the latter returning to baseline levels 10 to 11 months after treatment. Specific antibody responses remained protective during the study.With our proposed switch therapy, 4 out of 6 patients achieved a dramatic clinical improvement. This novel strategy targets different arms of the immune response and might be a good alternative for patients with severe AD." @default.
• W2130462370 created "2016-06-24" @default.
• W2130462370 creator A5019162070 @default.
• W2130462370 creator A5020417323 @default.
• W2130462370 creator A5035391740 @default.
• W2130462370 creator A5051329666 @default.
• W2130462370 creator A5062867071 @default.
• W2130462370 creator A5077220786 @default.
• W2130462370 creator A5080996618 @default.
• W2130462370 creator A5083778088 @default.
• W2130462370 date "2013-01-01" @default.
• W2130462370 modified "2023-10-18" @default.
• W2130462370 title "Sequential combined therapy with omalizumab and rituximab: a new approach to severe atopic dermatitis." @default.
• W2130462370 cites W1508479372 @default.
• W2130462370 cites W1512818159 @default.
• W2130462370 cites W1607245118 @default.
• W2130462370 cites W1763631360 @default.
• W2130462370 cites W1769055598 @default.
• W2130462370 cites W1956080051 @default.
• W2130462370 cites W1974217538 @default.
• W2130462370 cites W1978768695 @default.
• W2130462370 cites W1979167720 @default.
• W2130462370 cites W1987938816 @default.
• W2130462370 cites W1994233311 @default.
• W2130462370 cites W2022890273 @default.
• W2130462370 cites W2026119244 @default.
• W2130462370 cites W2026282632 @default.
• W2130462370 cites W2039756366 @default.
• W2130462370 cites W2040876247 @default.
• W2130462370 cites W2055967726 @default.
• W2130462370 cites W2062111746 @default.
• W2130462370 cites W2064119153 @default.
• W2130462370 cites W206701898 @default.
• W2130462370 cites W2077246374 @default.
• W2130462370 cites W2079204565 @default.
• W2130462370 cites W2085167576 @default.
• W2130462370 cites W2127891350 @default.
• W2130462370 cites W2141111992 @default.
• W2130462370 cites W2146172149 @default.
• W2130462370 cites W2166771071 @default.
• W2130462370 cites W2331277307 @default.
• W2130462370 cites W2346108732 @default.
• W2130462370 cites W2088574571 @default.
• W2130462370 cites W89924499 @default.
• W2130462370 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23967758" @default.
• W2130462370 hasPublicationYear "2013" @default.
• W2130462370 type Work @default.
• W2130462370 sameAs 2130462370 @default.
• W2130462370 citedByCount "8" @default.
• W2130462370 countsByYear W21304623702015 @default.
• W2130462370 countsByYear W21304623702017 @default.
• W2130462370 countsByYear W21304623702018 @default.
• W2130462370 countsByYear W21304623702019 @default.
• W2130462370 countsByYear W21304623702020 @default.
• W2130462370 crossrefType "journal-article" @default.
• W2130462370 hasAuthorship W2130462370A5019162070 @default.
• W2130462370 hasAuthorship W2130462370A5020417323 @default.
• W2130462370 hasAuthorship W2130462370A5035391740 @default.
• W2130462370 hasAuthorship W2130462370A5051329666 @default.
• W2130462370 hasAuthorship W2130462370A5062867071 @default.
• W2130462370 hasAuthorship W2130462370A5077220786 @default.
• W2130462370 hasAuthorship W2130462370A5080996618 @default.
• W2130462370 hasAuthorship W2130462370A5083778088 @default.
• W2130462370 hasConcept C126322002 @default.
• W2130462370 hasConcept C141105273 @default.
• W2130462370 hasConcept C159654299 @default.
• W2130462370 hasConcept C163864487 @default.
• W2130462370 hasConcept C18031839 @default.
• W2130462370 hasConcept C203014093 @default.
• W2130462370 hasConcept C2778329239 @default.
• W2130462370 hasConcept C2778564945 @default.
• W2130462370 hasConcept C2780653079 @default.
• W2130462370 hasConcept C542903549 @default.
• W2130462370 hasConcept C71924100 @default.
• W2130462370 hasConcept C90924648 @default.
• W2130462370 hasConceptScore W2130462370C126322002 @default.
• W2130462370 hasConceptScore W2130462370C141105273 @default.
• W2130462370 hasConceptScore W2130462370C159654299 @default.
• W2130462370 hasConceptScore W2130462370C163864487 @default.
• W2130462370 hasConceptScore W2130462370C18031839 @default.
• W2130462370 hasConceptScore W2130462370C203014093 @default.
• W2130462370 hasConceptScore W2130462370C2778329239 @default.
• W2130462370 hasConceptScore W2130462370C2778564945 @default.
• W2130462370 hasConceptScore W2130462370C2780653079 @default.
• W2130462370 hasConceptScore W2130462370C542903549 @default.
• W2130462370 hasConceptScore W2130462370C71924100 @default.
• W2130462370 hasConceptScore W2130462370C90924648 @default.
• W2130462370 hasIssue "3" @default.
• W2130462370 hasLocation W21304623701 @default.
• W2130462370 hasOpenAccess W2130462370 @default.
• W2130462370 hasPrimaryLocation W21304623701 @default.
• W2130462370 hasRelatedWork W170192676 @default.
• W2130462370 hasRelatedWork W1974217538 @default.
• W2130462370 hasRelatedWork W2015416183 @default.
• W2130462370 hasRelatedWork W2034060561 @default.
• W2130462370 hasRelatedWork W2078576151 @default.
• W2130462370 hasRelatedWork W2085700770 @default.
• W2130462370 hasRelatedWork W2351473942 @default.

• next